Establishment Labs Holdings Inc. $ESTA Stock Holdings Cut by CenterBook Partners LP

CenterBook Partners LP reduced its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 75.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 55,616 shares of the company’s stock after selling 167,229 shares during the quarter. CenterBook Partners LP’s holdings in Establishment Labs were worth $4,053,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quarry LP bought a new position in Establishment Labs during the 3rd quarter valued at $34,000. State of Wyoming bought a new position in Establishment Labs during the 3rd quarter valued at $71,000. Osaic Holdings Inc. boosted its stake in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares in the last quarter. Truist Financial Corp bought a new position in Establishment Labs during the 4th quarter valued at $200,000. Finally, PharVision Advisers LLC bought a new position in Establishment Labs during the 3rd quarter valued at $203,000. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on ESTA. Stephens increased their price target on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Needham & Company LLC raised their price objective on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Finally, BTIG Research raised their price objective on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.14.

Insiders Place Their Bets

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 330,000 shares of company stock worth $22,854,538 over the last quarter. 9.99% of the stock is currently owned by insiders.

Establishment Labs Stock Performance

ESTA opened at $74.84 on Tuesday. The firm has a market cap of $2.20 billion, a PE ratio of -50.23 and a beta of 1.11. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The business has a fifty day simple moving average of $66.79 and a 200-day simple moving average of $68.78. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.70) EPS. As a group, equities analysts predict that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.